Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8338485 | ALLERGAN | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
US8173708 | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
US8362085 | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
US8338486 | ALLERGAN | Methods for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
US8283379 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
US8580858 | ALLERGAN | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
US8329752 | ALLERGAN | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
US8598233 | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
US8168209 | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
US8293794 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
US8168209 (Pediatric) | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8598233 (Pediatric) | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8329752 (Pediatric) | ALLERGAN | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8173708 (Pediatric) | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8362085 (Pediatric) | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8283379 (Pediatric) | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(2 years from now) | |
US8039009 | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(5 years from now) | |
US8039009 (Pediatric) | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(6 years from now) | |
US8058291 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Dec, 2029
(6 years from now) |
Market Authorisation Date: 23 December, 2014
Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
70
United States
9
European Union
6
Canada
6
Japan
6
Australia
5
China
3
Brazil
3
Korea, Republic of
3
Mexico
2
Hong Kong
2
Germany
2
Russia
2
South Africa
1
Spain
1
Austria
1
Denmark
1
Poland
1
Singapore
1
EA
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic